vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.

Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $202.1M, roughly 1.7× CORCEPT THERAPEUTICS INC). Federal Realty Investment Trust runs the higher net margin — 38.6% vs 12.0%, a 26.6% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 8.7%). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 6.5%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.

CORT vs FRT — Head-to-Head

Bigger by revenue
FRT
FRT
1.7× larger
FRT
$336.0M
$202.1M
CORT
Growing faster (revenue YoY)
CORT
CORT
+2.4% gap
CORT
11.1%
8.7%
FRT
Higher net margin
FRT
FRT
26.6% more per $
FRT
38.6%
12.0%
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
6.5%
FRT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
FRT
FRT
Revenue
$202.1M
$336.0M
Net Profit
$24.3M
$129.7M
Gross Margin
98.7%
Operating Margin
2.2%
53.8%
Net Margin
12.0%
38.6%
Revenue YoY
11.1%
8.7%
Net Profit YoY
-21.0%
103.5%
EPS (diluted)
$0.20
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
FRT
FRT
Q1 26
$336.0M
Q4 25
$202.1M
$336.0M
Q3 25
$207.6M
$322.3M
Q2 25
$194.4M
$311.5M
Q1 25
$157.2M
$309.2M
Q4 24
$181.9M
$311.4M
Q3 24
$182.5M
$303.6M
Q2 24
$163.8M
$296.1M
Net Profit
CORT
CORT
FRT
FRT
Q1 26
$129.7M
Q4 25
$24.3M
$129.7M
Q3 25
$19.7M
$61.6M
Q2 25
$35.1M
$155.9M
Q1 25
$20.5M
$63.8M
Q4 24
$30.7M
$65.5M
Q3 24
$47.2M
$61.0M
Q2 24
$35.5M
$112.0M
Gross Margin
CORT
CORT
FRT
FRT
Q1 26
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Operating Margin
CORT
CORT
FRT
FRT
Q1 26
53.8%
Q4 25
2.2%
53.8%
Q3 25
4.9%
34.3%
Q2 25
13.7%
65.1%
Q1 25
2.2%
35.0%
Q4 24
13.9%
35.1%
Q3 24
25.5%
34.9%
Q2 24
21.7%
53.0%
Net Margin
CORT
CORT
FRT
FRT
Q1 26
38.6%
Q4 25
12.0%
38.6%
Q3 25
9.5%
19.1%
Q2 25
18.1%
50.0%
Q1 25
13.1%
20.6%
Q4 24
16.9%
21.0%
Q3 24
25.9%
20.1%
Q2 24
21.7%
37.8%
EPS (diluted)
CORT
CORT
FRT
FRT
Q1 26
$1.49
Q4 25
$0.20
$1.49
Q3 25
$0.16
$0.69
Q2 25
$0.29
$1.78
Q1 25
$0.17
$0.72
Q4 24
$0.25
$0.74
Q3 24
$0.41
$0.70
Q2 24
$0.32
$1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
FRT
FRT
Cash + ST InvestmentsLiquidity on hand
$372.2M
$107.4M
Total DebtLower is stronger
$5.0B
Stockholders' EquityBook value
$647.8M
$3.2B
Total Assets
$836.7M
$9.1B
Debt / EquityLower = less leverage
1.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
FRT
FRT
Q1 26
$107.4M
Q4 25
$372.2M
$107.4M
Q3 25
$421.7M
$111.3M
Q2 25
$342.2M
$177.0M
Q1 25
$322.8M
$109.2M
Q4 24
$383.3M
$123.4M
Q3 24
$380.3M
$97.0M
Q2 24
$473.2M
$103.2M
Total Debt
CORT
CORT
FRT
FRT
Q1 26
$5.0B
Q4 25
$5.0B
Q3 25
Q2 25
Q1 25
Q4 24
$4.5B
Q3 24
Q2 24
Stockholders' Equity
CORT
CORT
FRT
FRT
Q1 26
$3.2B
Q4 25
$647.8M
$3.2B
Q3 25
$631.9M
$3.2B
Q2 25
$635.8M
$3.2B
Q1 25
$683.3M
$3.2B
Q4 24
$679.6M
$3.2B
Q3 24
$638.8M
$3.1B
Q2 24
$596.2M
$3.0B
Total Assets
CORT
CORT
FRT
FRT
Q1 26
$9.1B
Q4 25
$836.7M
$9.1B
Q3 25
$823.6M
$8.9B
Q2 25
$801.7M
$8.6B
Q1 25
$846.5M
$8.6B
Q4 24
$840.6M
$8.5B
Q3 24
$784.3M
$8.5B
Q2 24
$714.6M
$8.4B
Debt / Equity
CORT
CORT
FRT
FRT
Q1 26
1.53×
Q4 25
1.53×
Q3 25
Q2 25
Q1 25
Q4 24
1.42×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
FRT
FRT
Operating Cash FlowLast quarter
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
FRT
FRT
Q1 26
Q4 25
$38.4M
$622.4M
Q3 25
$54.5M
$147.8M
Q2 25
$43.9M
$150.7M
Q1 25
$5.1M
$179.0M
Q4 24
$59.3M
$574.6M
Q3 24
$73.8M
$144.1M
Q2 24
$41.2M
$169.7M
Free Cash Flow
CORT
CORT
FRT
FRT
Q1 26
Q4 25
$38.4M
Q3 25
Q2 25
$43.9M
Q1 25
$5.0M
Q4 24
$59.2M
Q3 24
$72.2M
Q2 24
$40.8M
FCF Margin
CORT
CORT
FRT
FRT
Q1 26
Q4 25
19.0%
Q3 25
Q2 25
22.6%
Q1 25
3.2%
Q4 24
32.5%
Q3 24
39.5%
Q2 24
24.9%
Capex Intensity
CORT
CORT
FRT
FRT
Q1 26
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
Cash Conversion
CORT
CORT
FRT
FRT
Q1 26
Q4 25
1.58×
4.80×
Q3 25
2.77×
2.40×
Q2 25
1.25×
0.97×
Q1 25
0.25×
2.81×
Q4 24
1.93×
8.77×
Q3 24
1.56×
2.36×
Q2 24
1.16×
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons